The abortion-prone mating combination CBA/J × DBA/2 has been recognized as a model of preeclampsia, and complement activation has been implicated in the high rate of pregnancy loss observed in CBA/J mice. We have analyzed the implantation sites collected from DBA/2-mated CBA/J mice for the deposition of the complement recognition molecules using CBA/J mated with BALB/c mice as a control group. MBL-A was observed in the implantation sites of CBA/J × DBA/2 combination in the absence of MBL-C and was undetectable in BALB/c-mated CBA/J mice. Conversely, C1q was present in both mating combinations. Searching for other complement components localized at the implantation sites of CBA/J × DBA/2, we found C4 and C3, but we failed to reveal C1r. These data suggest that complement is activated through the lectin pathway and proceeds to completion of the activation sequence as revealed by C9 deposition. MBL-A was detected as early as 3.5 d of pregnancy, and MBL-A deficiency prevented pregnancy loss in the abortion-prone mating combination. The contribution of the terminal complex to miscarriage was supported by the finding that pregnancy failure was largely inhibited by the administration of neutralizing Ab to C5. Treatment of DBA/2-mated CBA/J mice with Polyman2 that binds to MBL-A with high affinity proved to be highly effective in controlling the activation of the lectin pathway and in preventing fetal loss.
Assisted reproduction techniques have improved considerably in recent decades, but despite these advances, success rates remain relatively low. Endometrial immune profiling involves the analysis of cytokine biomarkers in the endometrium during the mid-luteal phase. This profiling aims to provide insights into the immune environment of the uterus. The aim is to identify immune disturbances and thus guide the development of personalized therapeutic approaches. The first part of the review looks back at the emergence of innovative concepts, highlighting the specificity of the human uterine environment at the time of implantation. Based on this new knowledge, biomarkers have been selected for endometrial immune profiling. The second part details the results of clinical studies conducted over the last ten years. These clinical results suggest that this approach can increase the rate of live births in patients suffering from repeated implantation failures or repeated pregnancy loss. Uterine immune profiling represents a clinical innovation that can significantly improve the performance of medically assisted reproduction treatments through personalized strategies tailored to the local immune profile. Innovation in personalized medicine for assisted reproduction is crucial to improving the success rates of fertility treatments, while reducing the risks and costs associated with ineffective or unnecessary interventions.
Infertility affects millions of people of reproductive age. The failure of a blastocyst to implant is a leading cause of psychological distress. It became increasingly evident that an effective immune dialogue occurs at each step in the fluids surrounding the oocyte, the spermatozoa, the embryo, or the endometrium. Exploring and deciphering this dialogue could potentially help understand why 50% of healthy euploid blastocysts fail to implant. Introducing immunology into reproductive medicine requires a change of mindset to bring immune hypothesis to clinical applications. Implantation of an embryo requires a prepared uterus in order to dialogue with the embryo, which is able to express and repair itself. Exploring the uterine immune profile of patients with previous implantation failures (IF) or recurrent miscarriages (RM) has already been developed and is under evaluation as a precision tool to equilibrate the uterine environment before implantation to increase the subsequent live birth rate after the embryo transfer. Immunology may also be fundamental in the future to identify through non-invasive procedure the competence of oocytes or embryos through reliable immune biomarkers quantified in follicular fluids or embryo supernatants during the in vitro fertilization (IVF) process. Non-invasive biomarkers would allow physicians to identify competent oocytes or embryos based on their ability to communicate with the mother and their energetic potential for all the self-repair processes that should occur during the preimplantation and the implantation period. This area of research is only beginning.
Problem: Strong evidence suggests that the immune system plays a critical role in the progression and development of endometriosis. This study aims at assessing the endometrial immune profile in patients with endometriosis-associated recurrent implantation failures (RIFs) following in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), in comparison to women with male infertility-associated RIFs. Method of Study: This case-control study compared the endometrial immune profile in women with endometriosis-associated RIFs (case group) versus those with male infertility-associated RIFs (control group). The profile was evaluated using the ratio of IL-18/TWEAK mRNA expression levels (a biomarker for angiogenesis and Th1/Th2 balance), the ratio of IL-15/Fn14 mRNA expression levels (a biomarker for uNK cell activation/maturation), uNK cell counts, and CD56 mRNA expression levels (a marker for uNK cell mobilization). Results: The distribution of immune profiles significantly differed between the case group and the control group. The case group had fewer patients with a regulated profile (18.9% vs. 24.3%, P value 0.01) and more patients with under-activated profiles (34.2% vs. 28.4%, P value < 0.0001). Additionally, the case group had a higher proportion of immature uNK cells (46.2% vs. 39.2%, P value 0.007). The immaturity of uNK cells in endometriosis-associated RIFs appeared to be mediated by decreased IL-15 expression levels. Conclusions: The study highlights unique immune characteristics in the endometrial environment of women with endometriosis-associated RIFs, emphasizing the role of immune dysregulation in the development and progression of endometriosis.
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prespecified secondary analysis of a prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBRs) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type-specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs. 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Precision care improved LBR compared with conventional management (48.6% vs. 14.7%; OR 5.03 [1.66–17.63]; ARD +33.9%). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant to implantation success after frozen embryo transfer and warrants confirmation in larger prospective studies.
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBR) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type–specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Among dysregulated patients undergoing FET, precision care improved LBR compared with conventional management (48.6% vs 14.7%; OR 5.03 [1.66–17.63]). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant for optimizing implantation and live birth outcomes after frozen embryo transfer.